Work

CFTR Modulators for the Treatment of Cystic Fibrosis.

Year: 2014

Type: article

Abstract: Defects in a single gene lead to the defective proteins that cause cystic fibrosis, making the disease an ideal candidate for mutation-targeted therapy. Although ivacaftor is currently the only FDA-approved CFTR modifier, others are in development.

Source: PubMed Central

Authors: Rebecca S Pettit, Chris Fellner

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W1910988217

FWCI: 4.119

Cites: 47

Cited by: 72

Related to: 10